Based on previous data that SGK1 regulates INa4, we sought to identify small molecule SGK1 inhibitors for use as pharmacological probes to validate SGK1 as a therapeutic target in the treatment of cardiac arrhythmias. Here, SGK1 is linked to chronic obstructive pulmonary disease.